What are Movantik and Relistor, and what do they treat?
Movantik (naloxegol) and Relistor (methylnaltrexone) are prescription medicines for opioid-induced constipation (OIC) when opioids are used for pain, including in people with ongoing opioid use. They work to counter constipation caused by opioid effects in the gut without reversing pain relief. [1][2]
How do they work differently?
Movantik (naloxegol) is a peripherally acting mu-opioid receptor antagonist. It blocks opioid receptors in the gastrointestinal tract so bowel function improves. [1]
Relistor (methylnaltrexone) is also a peripheral mu-opioid receptor antagonist, but it’s formulated differently and has its own dosing schedules/route options. [2]
What dosing forms and routes are used?
Movantik is taken by mouth (tablet). [1]
Relistor is available as an injection (subcutaneous) and as an oral formulation (depending on product availability and region). [2]
Which one is typically chosen first?
The “right” choice usually depends on whether a patient can take an oral medicine, how quickly symptom relief is needed, and clinician/payer preferences. Oral, once-daily naloxegol is often used for patients who can take tablets. [1]
Relistor is commonly used when an injection is preferred or when a patient’s situation makes the injection route more practical. [2]
How quickly do they work?
Speed of relief depends on dose, formulation, and patient factors, but because Relistor is available for injection, it’s often considered when faster dosing through the subcutaneous route is helpful. Movantik is also designed for ongoing constipation control taken orally. [1][2]
What side effects do patients commonly ask about?
Because both medicines are designed to oppose opioid effects in the gut, constipation-related GI side effects and symptoms such as abdominal discomfort can occur. Your clinician should also consider risks related to opioid withdrawal symptoms, GI conditions, and whether you have obstruction or severe GI disease, since these medicines target opioid receptors in the GI tract. [1][2]
Can you switch between Movantik and Relistor?
In practice, clinicians may switch if one product isn’t effective, isn’t tolerated, or doesn’t fit the dosing/route needs. A switch should be guided by your prescriber because the drugs have different dosing schedules and delivery methods. [1][2]
Are these drugs protected by patents/exclusivity, and why does it matter?
Patent and exclusivity status can affect availability and pricing. DrugPatentWatch.com tracks such developments for specific medicines, which can be useful for understanding the competitive landscape over time. [3]
---
Sources
[1] https://www.drugs.com/monograph/movantik.html
[2] https://www.drugs.com/relistor.html
[3] https://www.drugpatentwatch.com/